Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virus-directed enzyme prodrug therapy using CB1954.

J I Grove1, P F Searle, S J Weedon

  • 1Cobra Therapeutics Ltd, The Science Park, Keele, Staffordshire, UK. groveji@cancer.bham.ac.uk

Anti-Cancer Drug Design
|June 2, 2000
PubMed
Summary

Virus-directed enzyme prodrug therapy (VDEPT) uses gene therapy to deliver a suicide gene into tumor cells. This gene activates a prodrug, CB1954, into a potent cancer-killing agent, demonstrating VDEPT

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cleared tissue dual-view oblique plane microscopy.

Biomedical optics express·2025
Same author

Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period.

Breast (Edinburgh, Scotland)·2025
Same author

HRD testing for all advanced high-grade ovarian carcinoma in first line?

ESMO open·2024
Same author

Editorial Expression of Concern: Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells.

Cancer gene therapy·2024
Same author

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet.

Pharmacological research·2023

Area of Science:

  • Oncology
  • Gene Therapy
  • Biochemistry

Background:

  • Virus-directed enzyme prodrug therapy (VDEPT) is an anti-cancer gene therapy strategy.
  • It utilizes viral vectors to deliver 'suicide genes' to tumor cells.
  • These genes encode enzymes that convert non-toxic prodrugs into cytotoxic agents.

Purpose of the Study:

  • To evaluate the efficacy of the enzyme-prodrug gene therapy system using Escherichia coli nitroreductase (Ntr) and the prodrug CB1954.
  • To assess the Ntr-CB1954 system's ability to sensitize tumor cells and induce bystander killing.
  • To compare this VDEPT approach with other VDEPT strategies.

Main Methods:

  • Delivery of the nitroreductase (Ntr) suicide gene into tumor cells using retroviral and adenoviral vectors.

Related Experiment Videos

  • Confirmation of Ntr expression via immunocytochemistry.
  • Treatment of Ntr-expressing and mixed cell populations with the prodrug CB1954.

    • Main Results:

    • Ntr expression was successfully achieved in vitro using viral vectors.
    • Ntr-expressing cells showed a significant sensitization to CB1954, up to 2000-fold.
    • The Ntr-CB1954 system demonstrated effective bystander killing in mixed cell populations.

    Conclusions:

    • The Ntr-CB1954 enzyme-prodrug system is a feasible and promising VDEPT strategy.
    • This approach effectively targets tumor cells and induces significant cytotoxicity.
    • The bystander effect enhances the therapeutic potential of this gene therapy.